“WHEREAS, Plaintiffs Bausch Health Ireland Limited and Salix Pharmaceuticals, Inc., (collectively, “Plaintiffs”), and Defendant Mylan Pharmaceuticals Inc., have agreed to the terms and conditions representing a negotiated settlement of this action and have set forth those terms and conditions in a Confidential Settlement and License Agreement (the “Settlement Agreement”), IT IS HEREBY STIPULATED AND AGREED, by and between Plaintiffs and Defendant, through their undersigned counsel of record, that: 1. The Complaints and all remaining claims, counterclaims, or affirmative defenses in the above action are dismissed with prejudice and without costs, disbursements, or attorney fees. 2. This Court will retain jurisdiction to enforce this Stipulation of Dismissal and the parties’ related agreements resolving this matter. 3. Plaintiffs acknowledge that Defendant is entitled to maintain its Case 1:22-cv-00020-TSK Document 296 Filed 05/14/25 Page 1 of 3 PageID #: 9098 2 Paragraph IV certification to U.S. Patent Nos. 7,041,786, 9,610,321, 9,616,097, 9,919,024, 9,925,231, 10,011,637, 11,142,549, 11,319,346, 11,834,521, and 12,146,003 pursuant to 21 C.F.R. § 314.94(a)(12)(v). 4. Each Party acknowledges and agrees that the 30-month stay with respect to the approval of the Mylan ANDA under 21 U.S.C. § 355(j)(5)(B)(iii) is expired. 5. Nothing herein shall prevent FDA from granting final approval to Mylan’s ANDA No. 215686 at any time, and Plaintiffs acknowledge that Mylan is entitled to pursue and obtain FDA approval for Mylan’s Abbreviated New Drug Application and the Mylan Product (as defined in the Parties’ Settlement Agreement) prior to expiration of U.S. Patent Nos. 7,041,786, 9,610,321, 9,616,097, 9,919,024, 9,925,231, 10,011,637, 11,142,549, 11,319,346, 11,834,521, and 12,146,003. 6. The Clerk of Court is directed to enter this Stipulation of Dismissal”